4SC provides Q2 2023 and H1 2023 update
- Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survival in CTCL patients and risk reduction of 38% compared to placebo
- Marketing Authorization Application for resminostat and nominated trade name of Kinselby accepted by EMA
- Kinselby uniquely positioned as maintenance treatment for CTCL
- Cash runway to Q3 2024
Planegg-Martinsried, Germany, 10 August 2023 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2023, presenting all material developments up to 30 June 2023 and the Company’s current outlook. The full communication is available for download on 4SC’s website.
